Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RSC
|
|||
| Former ID |
DNCL003077
|
|||
| Drug Name |
Sofinicline
|
|||
| Synonyms |
Sofinicline; ABT 894; Sofiniclin; ABT-894; UNII-SQC232V4YY; 799279-80-4; SQC232V4YY; CHEMBL238465; A-422894.0; Sofinicline [USAN:INN]; Sofinicline (USAN); SCHEMBL650488; A 422894.0;Sofiniclin; A 422894.0; MBQYQLWSBRANKQ-IMTBSYHQSA-N; BDBM50224483; ZINC28866069; CS-6792; DB12527; HY-14824; KB-74391; D09382; (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane; (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]-heptane; (1S,5S)-3-(5,6-Dichloro-pyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane; (1S, 5S)-3-(5,6-d
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 2 | [1] | |
| Company |
Abbott Laboratories; NeuroSearch
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H11Cl2N3
|
|||
| Canonical SMILES |
C1C2CN(CC2N1)C3=CC(=C(N=C3)Cl)Cl
|
|||
| InChI |
1S/C10H11Cl2N3/c11-8-1-7(3-14-10(8)12)15-4-6-2-13-9(6)5-15/h1,3,6,9,13H,2,4-5H2/t6-,9+/m0/s1
|
|||
| InChIKey |
MBQYQLWSBRANKQ-IMTBSYHQSA-N
|
|||
| CAS Number |
CAS 799279-80-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) | Target Info | Modulator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.